XML 113 R67.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Net deferred tax position (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Income Taxes [Abstract] |
Summary of Net Deferred Tax Position | An analysis of the net deferred tax position is set forth below:
(€ million) | 2023 |  | 2022 |  | 2021 |
Deferred taxes on: |  |  |  |  |  |
Consolidation adjustments (intragroup margin in inventory) | 1,525 |  |  | 1,388 |  |  | 1,292 |  |
Provision for pensions and other employee benefits | 853 |  |  | 850 |  |  | 1,117 |  |
Remeasurement of other acquired intangible assets | (2,904) |  | (a) | (3,269) |  |  | (3,079) |  |
Recognition of acquired property, plant and equipment at fair value | (21) |  |  | (24) |  |  | (26) |  |
Equity interests in subsidiaries and investments in other entities(b) | (1,023) |  |  | (617) |  |  | (590) |  |
Tax losses available for carry-forward | 1,526 |  |  | 1,506 |  |  | 1,516 |  |
Stock options and other share-based payments | 84 |  |  | 92 |  |  | 88 |  |
Accrued expenses and provisions deductible at the time of payment(c) | 1,994 |  |  | 1,859 |  |  | 1,585 |  |
Other(d) | 2,536 |  |  | 1,755 |  |  | 1,078 |  |
Net deferred tax asset/(liability) | 4,570 |  |  | 3,540 |  |  | 2,981 |  |
(a) As of December 31, 2023, includes remeasurements of the acquired intangible assets of Bioverativ (€1,241 million), Principia (€610 million), Ablynx (€204 million), Genzyme (€50 million) and Amunix (€109 million). (b) In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately €60.4 billion) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2023, Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December 31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October 2023 (see Note D.30.). (c) Includes deferred tax assets related to restructuring provisions, amounting to €286 million as of December 31, 2023, €256 million as of December 31, 2022, and €226 million as of December 31, 2021. (d) Includes deferred taxes arising on the spread tax deduction of R&D expenses, amounting to €1,331 million as of December 31, 2023 and €742 million as of December 31, 2022.
Summary of Tax Losses Available for Carry-forward | The table below shows when tax losses available for carry-forward are due to expire:
(€ million) | Tax losses available for carry-forward(a)
2024 | 6 |
2025 | 7 |
2026 | 34 |
2027 | 23 |
2028 | 126 |
2029 and later | 8,737 |
Total as of December 31, 2023 | 8,933 |
Total as of December 31, 2022 | 8,503 |
Total as of December 31, 2021 | 7,644 |
(a) Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to €5 million as of December 31, 2023, €5 million as of December 31, 2022 and €5 million as of December 31, 2021.

X
- Definition The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 12 -IssueDate 2023-01-01 -Paragraph 81 -Subparagraph g -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of availability of tax losses carry forwards. + References No definition available. + Details
Name: | sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Income Taxes [Abstract] + References No definition available. + Details
Name: | sny_IncomeTaxesAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration